GlassScriptPhysician profile
David M Katz
NPI 1740283480
$164,270.80
in general payments reported to CMS, 2019-2025
20 companies · $539 in 2025
The $539 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85K · 2020: $26K · 2021: $16K · 2022: $26K · 2023: $11K · 2024: $565 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,998 · Food and Beverage: $2,425 · Travel and Lodging: $664 · Education: $2.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,997.50 |
| Food and Beverage | $2,424.89 |
| Travel and Lodging | $664.12 |
| Education | $2.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $114,846.36 | 2019-2023 | Vumerity, Tysabri, Plegridy |
| Alexion Pharmaceuticals, INC. | $43,951.15 | 2019-2023 | Ultomiris |
| Banner Life Sciences, LLC | $1,700.00 | 2020-2021 | |
| Emd Serono, INC. | $843.70 | 2019-2024 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $773.24 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $705.94 | 2019-2024 | Austedo Xr, Ajovy |
| Ucb, INC. | $230.92 | 2023-2025 | Rystiggo, Zilbrysq |
| Horizon Therapeutics Plc | $228.21 | 2020-2023 | Uplizna, Tepezza |
| Amgen INC. | $189.29 | 2024-2025 | Uplizna, Tepezza |
| Glaukos Corporation | $188.67 | 2025 | Idosetr |
| Tg Therapeutics, INC. | $183.91 | 2023-2025 | |
| Allergan, INC. | $183.05 | 2019-2020 | |
| Genentech USA, INC. | $84.43 | 2023-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Genentech, INC. | $70.80 | 2023 | Enspryng |
| Genzyme Corporation | $27.03 | 2019-2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $19.72 | 2023 | Supera |
| Abbvie INC. | $15.51 | 2022 | |
| Sunovion Pharmaceuticals INC. | $14.74 | 2020 | |
| Argenx US, INC. | $14.13 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Katz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.